CTRI/2011/08/001977尚未招募4 期
The Impact Of Nicotinic acid (Niacin) And Laropiprant (LRPT) On Increased Triglyceride more than 300 And its implications with low High Density Lipoprotein Cholesterol (males less than 40 females less than 45) - TRIDL study
Sub arm study of PURSE HIS funded by Department of Science and Technology Government of India0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Human participants attending cardiology op and PURSE-HIS study, of age group 18 to advanced age with isolated or combined hypertriglyceridemia of both sexes, who have given written informed consent to participate in the study and agree for all presaid examinations
排除标准
- •Pregnant and lactating female participants.
- •Hypersensitivity to the active substances or to the any of the excipients.
- •Participants with significant or unexplained hepatic dysfunction.
- •Active peptic ulcer disease.
- •Arterial bleeding.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLaipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term.EUCTR2006-005710-12-DECharité Universitätsmedizin Berlin150
进行中（未招募）
不适用
Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemiaDyslipoproteinemiaMedDRA version: 12.1Level: LLTClassification code 10063903Term: DyslipoproteinemiaMedDRA version: 12.1Level: LLTClassification code 10052066Term: Metabolic syndromeEUCTR2010-019954-42-DEMed. Klinik II, Klinikum der Universität München Grosshadern
进行中（未招募）
1 期
The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease - Niaspan in CKDChronic renal failure (CKD stages 4 &%)EUCTR2005-002982-35-GBBarts and The London NHS Trust
进行中（未招募）
不适用
Efecto de niacina/laropiprant en la concentración de lipoproteína (A) en relación a las concentraciones basales y al tamaño de lipoproteína (A).EUCTR2010-022258-17-ESInstituto Aragonés de Ciencias de la Salud
已完成
2 期
A Comparative study on the effet of Niacin and Sevelamer on decreasing the phosphorous in dialysis patients referring to dialysis department of 5azar medical education center of gorgan in2019(1398)IRCT20190324043106N1Gorgan University of Medical Sciences76